- Home
- PI vs VRDN Comparison
PI vs VRDN Comparison
Compare PI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PI
- VRDN
- Stock Information
- Founded
- PI 2000
- VRDN 2006
- Country
- PI United States
- VRDN United States
- Employees
- PI N/A
- VRDN N/A
- Industry
- PI Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- PI Technology
- VRDN Health Care
- Exchange
- PI Nasdaq
- VRDN Nasdaq
- Market Cap
- PI 1.9B
- VRDN 1.6B
- IPO Year
- PI 2016
- VRDN N/A
- Fundamental
- Price
- PI $100.00
- VRDN $12.39
- Analyst Decision
- PI Strong Buy
- VRDN Buy
- Analyst Count
- PI 8
- VRDN 14
- Target Price
- PI $149.00
- VRDN $36.82
- AVG Volume (30 Days)
- PI 777.7K
- VRDN 887.1K
- Earning Date
- PI 04-23-2025
- VRDN 05-06-2025
- Dividend Yield
- PI N/A
- VRDN N/A
- EPS Growth
- PI N/A
- VRDN N/A
- EPS
- PI N/A
- VRDN N/A
- Revenue
- PI $363,539,000.00
- VRDN $302,000.00
- Revenue This Year
- PI N/A
- VRDN N/A
- Revenue Next Year
- PI $26.78
- VRDN $20,553.29
- P/E Ratio
- PI N/A
- VRDN N/A
- Revenue Growth
- PI 21.80
- VRDN 4.86
- 52 Week Low
- PI $60.85
- VRDN $9.90
- 52 Week High
- PI $239.88
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PI 65.44
- VRDN 42.19
- Support Level
- PI $94.81
- VRDN $11.76
- Resistance Level
- PI $100.22
- VRDN $13.63
- Average True Range (ATR)
- PI 4.30
- VRDN 0.75
- MACD
- PI 2.19
- VRDN -0.02
- Stochastic Oscillator
- PI 91.01
- VRDN 22.11
About PI Impinj Inc.
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.